High Content Imaging and 3D Cultures

Our state-of-the-art ImageXpress® Micro Confocal (IXM-C) High Content Imaging platform provides multi-dimensional, High-throughput Screening solutions to facilitate compound profiling, MOA analysis and; through the use of highly relevant in vitro models, to support interrogation of compound safety.

High Content Imaging

The IXM-C allows our scientists to capture high content imaging with a wide range of objective lenses, and the possibility to multiplex up to 5 wavelengths together with transmitted light. The high content imaging mode options of widefield and confocal provide the sensitivity and resolution required for a given assay. Combined with MetaXpress® High-Content Power Core Image Acquisition and Analysis Software, the ImageXpress® Micro Confocal system provides a complete multi-dimensional, high-throughput screening solution.

High Content Screening

3D cultures more closely resemble the in vivo tissue environment due to the promotion of cell-cell contacts, re-establishment of cell polarity and the production of extracellular matrices. At Sygnature Discovery we offer expertise in the high content multi-parametric imaging/screening of 3D cell cultures using the IXM-C platform for the evaluation of compound dependent effects on a number of clinically relevant parameters.

A range of assay formats are available and are applicable to multiple phases of the drug discovery process, including target identification, hit validation and candidate drug profiling.

Current assays available include:

Examples include:

Viability, cytotoxicity, phospholipidosis, mitochondrial toxicity

Mitochondrial Depolarisation:

Chlorpromazine - Mitochondrial membrane depolarisation

Neurite Dynamics:

MicroConfocal Neurite Outgrowth Assay - PC12 Neuronal cells in absense or presense of NGF Co-Culture of Endothelial cells and Normal Human Dermal Fibroblasts

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…